The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...
75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation ...
INGELHEIM, Germany and RIDGEFIELD, Conn., Oct. 17, 2025 /PRNewswire/ -- Boehringer Ingelheim reported positive results from the Beamion LUNG-1 trial evaluating HERNEXEOS® (zongertinib tablets) in ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients 12 mg/kg selected as optimal dose for extension part of ...
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 ...
SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced ...
Please provide your email address to receive an email when new articles are posted on . A trial investigating mirvetuximab soravtansine monotherapy in certain patients with platinum-sensitive ovarian ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback